TB-500 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-18. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
| Property | Value | Notes |
|---|---|---|
| Dosage form | Lyophilized powder in sealed vial | Reconstituted before analytical or laboratory use |
| Reconstitution solvent | Sterile or bacteriostatic water | Bacteriostatic water limits microbial growth in multi-use vials |
| Typical working pH | Near neutral, buffered | Strongly acidic or basic conditions promote degradation |
| Stability indicator | Loss of main HPLC peak over time | Aggregation and oxidation are common degradation routes |
| Documentation | Batch certificate of analysis | Covers identity, purity and sometimes sterility testing |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
=== United States plan === Immediate ceasefire: An immediate end to hostilities between the US (and Israel) and Iran. Two-phase agreement structure: Reopening the Strait of Hormuz: Iran must immediately reopen the Strait of Hormuz, restoring global oil flow. Guaranteed maritime security: Creating a regional framework ensuring safe navigation through the Strait of Hormuz. Nuclear constraints on Iran: Iran commits to stop its alleged pursuit of nuclear weapons as part of the final deal Sanctions relief (conditional): The US signaled willingness to ease sanctions, but only in exchange for Iranian concessions. Release of frozen Iranian assets: Part of incentives included unfreezing Iranian funds abroad Structured negotiations via mediators: All talks will be channeled through Pakistan initially, then finalized in Islamabad. Possible extended ceasefire window: During Phase 2 the discussions will be over a period of 45 days. Broader regional de-escalation: The agreement aims to stabilize additional conflicts in the Middle East, not just the war with Iran.
== External links == Histology image: 21301loa – Histology Learning System at Boston University - "Ultrastructure of the Cell: myelinated axon and Schwann cell" Histology image: 21401loa – Histology Learning System at Boston University - "Ultrastructure of the Cell: arteriole and peripheral nerve" Histology image: 1_03 at the University of Oklahoma Health Sciences Center Histology at University of California, Los Angeles Diagram at Howard University
The coexistence of intense, divergent moods within an individual was recognized by Homer, Hippocrates, and Aretaeus, the last describing the vacillating presence of impulsive anger, melancholia, and mania within a single person. Swiss physician Théophile Bonet revived the concept in 1684, and used the term folie maniaco-mélancolique to describe the phenomenon of unstable moods that followed an unpredictable course. Other writers noted the same pattern, including the American psychiatrist Charles H. Hughes in 1884 and J. C. Rosse in 1890, who called the disorder "borderline insanity". In 1921, Emil Kraepelin identified an "excitable personality" that closely parallels the borderline features outlined in the current concept of BPD. The idea that there were forms of disorder that were neither psychotic nor simply neurotic began to be discussed in psychoanalytic circles in the 1930s. The first formal definition of borderline disorder is widely acknowledged to have been written by Adolph Stern in 1938. He described a group of patients who he felt to be on the borderline between neurosis and psychosis, who often came from family backgrounds marked by trauma. He argued that such patients would often need more active support than that provided by classical psychoanalytic techniques. The 1960s and 1970s saw a shift from thinking of the condition as borderline schizophrenia to thinking of it as a borderline affective disorder (mood disorder), on the fringes of bipolar disorder, cyclothymia, and dysthymia.
A compromise solution was worked out whereas the infantry would attack north from both sides of Lake Ilmen, while the panzer group would advance from its current position. Hoepner's forces began their advance on August 8, but the attack ran into determined Soviet defences. Elsewhere, Soviet counter-attacks threatened Leeb's southern flank. By mid to late August, the German forces were making gains again, with the 4th Panzer Group taking Narva on 17 August. On 29 August, Leeb issued orders for the blockade of Leningrad in anticipation that the city would soon be abandoned by the Soviets. On September 5, Hitler ordered Hoepner's 4th Panzer Group and an air corps transferred to Army Group Centre effective 15 September, in preparation for Operation Typhoon, the German assault on Moscow. Leeb objected and was given a reprieve in the transfer of his mobile forces, with the view of making one last push towards Leningrad. The 4th Panzer Group was to be the main attacking force, which reached south of the Neva River, where it was faced with strong Soviet counter-attacks. By 24 September, Army Group North halted its advance and transferred the 4th Panzer Group to Army Group Centre.
Sources: en.wikipedia.org
which is the expression for the strain energy density of a Neo-Hookean solid. Several compressible versions of the Gent model have been designed. One such model has the form (the below strain energy function yields a non zero hydrostatic stress at no deformation, refer for compressible Gent models).
Ahmedin Muktar Jemal is an American cancer epidemiologist who serves as senior vice president of the Surveillance & Health Equity Science Department of the American Cancer Society. He has been researching racial differences in lung cancer rates since the mid-1990s, when he was a fellow at the National Cancer Institute.
Flavoring are often added to e-liquids as well as dry smoke blends. There are currently over 7,700 e-liquid flavors available, most have not been laboratory tested for toxicity. There are numerous flavors (e.g., fruit, vanilla, caramel, coffee) of e-liquid available. There are also flavorings that resemble the taste of cigarettes.
dosage compensation Any mechanism by which organisms neutralize the large difference in gene dosage caused by the presence of differing numbers of sex chromosomes in the different sexes, thereby equalizing the expression of sex-linked genes so that the members of each sex receive the same or similar amounts of the products of such genes. An example is X-inactivation in female mammals.
Most of the organic carbon in CI and CM carbonaceous chondrites is an insoluble complex material. That is similar to the description for kerogen. A kerogen-like material is also in the ALH84001 Martian meteorite (an achondrite). The CM meteorite Murchison has over 96 extraterrestrial amino acids and other compounds including carboxylic acids, hydroxy carboxylic acids, sulphonic, and phosphonic acids, aliphatic, aromatic, and polar hydrocarbons, fullerenes, heterocycles, carbonyl compounds, alcohols, amines, and amides.
Sources: en.wikipedia.org
The process continues until the rate of release of new electrons in collisions is balanced by the rate of recombination of electrons with argon ions (atoms that have lost an electron). This produces a ‘fireball’ that consists mostly of argon atoms with a rather small fraction of free electrons and argon ions.
== Adrenomedullary hormones == Adrenomedullary hormones are catecholamines secreted from the adrenal medulla by chromaffin cells, neurosecretory cells connected to the central nervous system. The synthesis, storage (in chromaffin cells) and release of catecholamines is co-regulated by synaptic input from their respective pre-synaptic sympathetic neurons, as well as hormonal and local inputs. The adrenomedullary hormones are:
The report also stated that the Sinaloa Cartel was colluding with the government to destroy other cartels and protect itself and its leader, "El Chapo" Guzmán. Mexican officials have denied any corruption in the government's treatment of cartels.
== Biomarker == Fragments derived from the ANP precursor, including the signal peptide, NT-ProANP (N-terminal pro-ANP) and ANP, have been detected in human blood. ANP (28 residues long) is the active hormone while NT-proANP (98 residues) is the remaining part of proANP after cleavage by corin. ANP and associated peptides are used as biomarkers for cardiovascular diseases such as stroke, coronary artery disease, myocardial infarction and heart failure. A part of NT-proANP called mid-regional pro-atrial natriuretic peptide (MR-proANP) is a highly sensitive biomarker in heart failure. MR-proANP levels below 120 pmol/L can be used to effectively rule out acute heart failure. MR-proANP is measured using antibodies that bind to two consecutive parts of NT-proANP, residue number 53–72 and 73–90. In contrast, traditional NT-proANP measurement use antibodies that bind to the N-terminal of NT-proANP. In either case, antibodies are only able to determine the amount of peptides matching their epitope fragments. They largely cannot differentiate between a cleaved part (NT-proANP, ANP) and the uncleaved precursor (proANP). Large amounts of ANP secretion has been noted to cause electrolyte disturbances (hyponatremia) and polyuria. These indications can be a marker of a large atrial myxoma.
Amino acids are the precursors to proteins. They join by condensation reactions to form short polymer chains called peptides or longer chains called either polypeptides or proteins. These chains are linear and unbranched, with each amino acid residue within the chain attached to two neighboring amino acids. In nature, the process of making proteins encoded by RNA genetic material is called translation and involves the step-by-step addition of amino acids to a growing protein chain by a ribozyme that is called a ribosome. The order in which the amino acids are added is read through the genetic code from an mRNA template, which is an RNA derived from one of the organism's genes. There are 22 amino acids that get naturally incorporated into polypeptides; these are called proteinogenic amino acids or natural amino acids. Of these, 20 are encoded by the universal genetic code. The remaining 2, selenocysteine and pyrrolysine, are incorporated into proteins by unique synthetic mechanisms. Selenocysteine is incorporated when the mRNA being translated includes a SECIS element, which causes the UGA codon to encode selenocysteine instead of a stop codon. Pyrrolysine is used by some methanogenic archaea in enzymes that they use to produce methane. It is coded for with the codon UAG, which is normally a stop codon in other organisms.
Sources: en.wikipedia.org
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.
It usually reports batch-specific results for purity by chromatography, identity by mass spectrometry, and sometimes peptide content and residual solvents. It applies only to the batch tested, not to a supplier's wider stock.
Purity describes the proportion of the chromatographic signal from the target compound, while peptide content measures how much of the vial's physical mass is peptide. Counter-ions, water and residual acid make up the remainder, so content values are commonly lower.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.